Deerfield Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Deerfield Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-333,333	Closed	-$13.5K	–	118
2023 Q1	$13.5K	Hold	333,333	–	–	﹤0.01%	104
2022 Q4	$18.5K	Hold	333,333	–	–	﹤0.01%	101
2022 Q3	$13K	Hold	333,333	–	–	﹤0.01%	121
2022 Q2	$22K	Hold	333,333	–	–	﹤0.01%	121
2022 Q1	$62K	Hold	333,333	–	–	﹤0.01%	115
2021 Q4	$193K	Buy	+333,333	New	+$245K	﹤0.01%	120

Deerfield Management's EUCRW Position: Q2 2023 in Review

Deerfield Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 333,333 shares — an estimated $13.5K sold.

Deerfield Management first reported a position in EUCRW in Q4 2021 and held it in 6 quarters. The position peaked at $193K in Q4 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Deerfield Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Deerfield Management sold 333,333 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $13.5K.
Deerfield Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q4 2021 and held it in 6 quarters.
Deerfield Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $193K in Q4 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.